31 results about "Neuromuscular Blockade" patented technology

The invention aims to provide an anesthesia depth monitoring device and an anesthesia depth monitoring method. According to the anesthesia depth monitoring device disclosed by the invention, by carrying out analysis and transverse comparison on a bispectral index, noxious stimulation data and neuromuscular blockade depth data, injection medicine is respectively controlled, the interference of the neuromuscular blockade recovery and the noxious stimulation strengthening on the electroencephalogram monitoring anesthesia depth is effectively eliminated and the monitoring on the electroencephalogram anesthesia depth can accurately and effectively reflect an anesthesia depth value of a patient. Meanwhile, by the anesthesia control of carrying out interference elimination on the monitoring on the electroencephalogram anesthesia depth and then carrying out optimization, the anesthesia depth can be controlled stable like a straight line, the machine control of the integral anesthesia process is implemented, the condition of judging the anesthesia process mainly by the anesthesia experience of a doctor is changed, the influence of the individual difference of patients is overcome, the safety of the anesthesia process is furthest ensured and the anesthesia depth monitoring device and the anesthesia depth monitoring method have high social values and a wide application prospect.

The invention relates to the use of chemical chelators for the preparation of a medicament for the reversal of drug-induced neuromuscular block, to a kit for providing neuromuscular block and its reversal, and to cyclophane derivatives having general formula (A) wherein R is (a), (b) or (c); or general formula (B) wherein X is (a), (b) or (d), or a pharmaceutically acceptable salt thereof.

The invention describes antibiotics, muscle relaxants and plant extracts that have neuromuscular blockade effects as well as methods of use thereof. These compounds can be used in the same clinical settings as botulinum toxin and may be used topically, thereby providing an advantage over botulinum toxin in terms of application and ease of use. The compounds can be used in pharmaceutical compositions for the treatment of involuntary muscle spasms and neuropathic pain and in cosmetic compositions for the treatment of facial wrinkles. Also provided are kits useful for therapeutic and/or cosmetic applications.

The invention discloses a multiple-address controllable miniature neuromuscular blockade electrical stimulation system and belongs to the field of medical apparatuses and instruments. The multiple-address controllable miniature neuromuscular blockade electrical stimulation system comprises an in-vitro controller and multiple in-vivo miniature electrical stimulators, each in-vivo miniature electrical stimulator is provided with a fixed address, the in-vitro controller controls synchronous working of each miniature electrical stimulator through an instrument and provides energy required by electrical stimulation through wireless radio frequency and transmits an electrical stimulation command. The system multiple-address controllable miniature neuromuscular blockade electrical stimulation system sends the instrument to control the synchronous working of each miniature electrical stimulator through one in-vitro controller, achieves multiple-muscle-group coordinated exercise, perfects basic exercise of a human body, effectively solves the multiple-muscle-group coordinated shrinkage problem, and solves the problem that a traditional implanted product can only simulate muscle groups and the problem of replacement operation caused by battery service life.

The invention aims at providing an anaesthetic balance control device. The device comprises a data filter module and a drug balance control module. Pre-stored electrocerebral indexes, noxious stimulation data drug usage data are divided into electrocerebral index-sedative data and noxious stimulation data-sedative data. Corresponding drug target control indexes are selected according to electrocerebral index and noxious stimulation data changes in certain period, threshold values are preset, and injection of muscle relaxants are increased or stopped based on the set threshold values. Meanwhile, bispectral index, noxious stimulation data, neuromuscular retarding depth data change tendency slope and the like can be analyzed dynamically, and transverse balance adjusting control is performed on three signals. The invention further provides a work method of the device. According to the device and the method, the problem the imbalanced usage of three drugs is solved, effects of individual differences are prevented, the safety during anesthesia is guaranteed to the largest extent, and good social values and application prospects are provided.

Methods and kits for treating or reducing the likelihood of neurotoxin-induced respiratory failure in a subject, such as a victim of neurotoxic envenomation are provided. Also provided are methods for treating or reducing the likelihood of residual neuromuscular blockade in a subject to whom a nondepolarizing neuromuscular blocking agent has been administered. The methods involve administering a pharmaceutically effective dose of an acetylcholinesterase inhibitor to the subject, where the administration is not via injection. In some embodiments intra-nasal or ocular administration is used.

Sensors are provided for monitoring neuromuscular blockade in patients. In one embodiment, a sensor includes a first flexible substrate including a sensing element for measuring patient response to a stimulus, a second flexible substrate for providing the stimulus, the second flexible substrate including at least two electrodes, the first flexible substrate not connected to the second flexible substrate, and a common connector coupled to both the first flexible substrate and the second flexible substrate, the connector configured to couple to an NMT monitoring device.

The present disclosure relates to various methods for determining a neuromuscular blockade status and systems suitable for performing such methods. The present disclosure further relates to electro-stimulation electrodes for stimulating a muscle of a patient, optionally in the context of at least some of the mentioned methods. The present disclosure still further relates to hybrid air-signal connectors for use in an electro-stimulation cuff which can be used in the context of at least some of the cited methods. The present disclosure also relates to electro-stimulation circuits comprising an electrode portion and a track portion suitable for pressure cuffs for electro-stimulation, and to pressure cuffs configured to be arranged around a limb of a patient and comprising an active electro-stimulation electrode and a passive electro-stimulation electrode. These electro-stimulation circuits and pressure cuffs may also be used in the context of at least some of the mentioned methods.

The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel.

Provided are methods for reversing the effects of agents used for muscular immobilization and/or loss of consciousness and/or loss of pain perception. The method comprises administering a composition comprising acyclic CB[n]-type compounds to an individual in need of reversal of the effects of neuromuscular blocking agents and/or anesthetic agents such that the effects of the agent(s) are partially fully reversed.

The present disclosure relates to various methods for determining a neuromuscular blockade status and systems suitable for performing such methods. The present disclosure further relates to electro-stimulation electrodes for stimulating a muscle of a patient, optionally in the context of at least some of the mentioned methods. The present disclosure still further relates to hybrid air-signal connectors for use in an electro-stimulation cuff which can be used in the context of at least some of the cited methods. The present disclosure also relates to electro-stimulation circuits comprising an electrode portion and a track portion suitable for pressure cuffs for electro-stimulation, and to pressure cuffs configured to be arranged around a limb of a patient and comprising an active electro-stimulation electrode and a passive electro-stimulation electrode. These electro-stimulation circuits and pressure cuffs may also be used in the context of at least some of the mentioned methods.

The invention discloses a new compound for muscle relaxation antagonism. The new compounds of theta type, beta type, gamma type, lambda type, kappa type, nu type, tau type, omega type, upsilon type and the like of sugammadex sodium have less hygroscopicity and better storage stability, are more beneficial to quality control of medicines and preparations and the like, and are suitable for preparingspecific binding neuromuscular block antagonists. And the compound can be applied to drugs for antagonizing treatment or prevention of neuromuscular block induced by rocuronium bromide or vecuroniumbromide and the like.

The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel.

A neuromuscular blocking preparation for blocking and/or alleviating a vasospasm is provided, the preparation comprising a plurality of gas-or a gas precursor-filled microspheres, and a neuromuscular blocking agent. Methods for using such a preparation for blocking and/or alleviating a vasospasm are also provided.

The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC-1 ion channel.